These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 26763986

  • 1. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A.
    Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M.
    J Clin Oncol; 2016 Apr 10; 34(11):1175-81. PubMed ID: 26712220
    [Abstract] [Full Text] [Related]

  • 3. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
    Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B.
    Cochrane Database Syst Rev; 2017 May 25; 5(5):CD007941. PubMed ID: 28541603
    [Abstract] [Full Text] [Related]

  • 4. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O.
    Br J Haematol; 2017 Sep 25; 178(5):709-718. PubMed ID: 28589704
    [Abstract] [Full Text] [Related]

  • 5. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B.
    Lancet Haematol; 2021 Apr 25; 8(4):e278-e288. PubMed ID: 33770483
    [Abstract] [Full Text] [Related]

  • 6. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 7. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E, Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F, Engert A, Arasteh K, Hoffmann C.
    J Clin Oncol; 2012 Nov 20; 30(33):4117-23. PubMed ID: 23045592
    [Abstract] [Full Text] [Related]

  • 8. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
    Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N.
    J Clin Oncol; 2016 Jun 10; 34(17):2028-36. PubMed ID: 27114593
    [Abstract] [Full Text] [Related]

  • 9. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
    Filatova LV, Plotnikova AA, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2013 Jun 10; 59(2):59-65. PubMed ID: 23814851
    [Abstract] [Full Text] [Related]

  • 10. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG, HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    J Clin Oncol; 2009 Feb 10; 27(5):805-11. PubMed ID: 19124807
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A.
    J Clin Oncol; 2017 Jun 20; 35(18):1999-2007. PubMed ID: 28418763
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin's lymphoma.
    Lin N, He C, Zhang Q, Hong X, Liu L, Yang S, Su H, Li X, Dai X, Li Y, Zhu J.
    J Cancer Res Ther; 2024 Aug 01; 20(4):1258-1264. PubMed ID: 39206988
    [Abstract] [Full Text] [Related]

  • 13. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.
    Ann Hematol; 2016 Apr 01; 95(5):809-16. PubMed ID: 26878861
    [Abstract] [Full Text] [Related]

  • 14. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
    Tarasenkova AA, Filatova LV, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2012 Apr 01; 58(1):101-9. PubMed ID: 22629838
    [Abstract] [Full Text] [Related]

  • 15. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
    André MPE, Carde P, Viviani S, Bellei M, Fortpied C, Hutchings M, Gianni AM, Brice P, Casasnovas O, Gobbi PG, Zinzani PL, Dupuis J, Iannitto E, Rambaldi A, Brière J, Clément-Filliatre L, Heczko M, Valagussa P, Douxfils J, Depaus J, Federico M, Mounier N.
    Cancer Med; 2020 Sep 01; 9(18):6565-6575. PubMed ID: 32710498
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A.
    Br J Haematol; 2014 Jul 01; 166(1):118-29. PubMed ID: 24673727
    [Abstract] [Full Text] [Related]

  • 17. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
    André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J.
    J Clin Oncol; 2017 Jun 01; 35(16):1786-1794. PubMed ID: 28291393
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.
    J Clin Oncol; 2011 Nov 10; 29(32):4227-33. PubMed ID: 21990405
    [Abstract] [Full Text] [Related]

  • 19. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 20. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P.
    Hematol Oncol Clin North Am; 2014 Feb 20; 28(1):65-74. PubMed ID: 24287068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.